Intellia Therapeutics Inc
NTLA9.520USD
-2.800-22.73%
收盤 11/07, 16:00（美東）報價延遲15分鐘
985.70M總市值
虧損本益比TTM
關於 Intellia Therapeutics Inc 公司
Intellia Therapeutics, Inc. 是一家臨牀階段的基因組編輯公司，專注於使用成簇、規律間隔的短迴文重複序列/CRISPR 相關 9 (CRISPR/Cas9) 技術開發治癒性療法。CRISPR/Cas9 是一種基因組編輯技術，即改變基因組脫氧核糖核酸的選定序列的過程。該公司專注於利用其模塊化平臺推進體內和體外治療高度未滿足需求的疾病。其領先的體內候選藥物 NTLA-2001 用於治療轉甲狀腺素蛋白 (ATTR) 澱粉樣變性，而 NTLA-2002 用於治療遺傳性血管性水腫 (HAE)，是首批通過靜脈 (IV) 輸注全身給藥的基於 CRISPR/Cas9 的治療候選藥物，用於精確編輯人類靶組織中的基因。該公司還在開發體外應用以治療免疫腫瘤學和自身免疫性疾病。
Intellia Therapeutics Inc簡介
公司代碼NTLA
公司名稱Intellia Therapeutics Inc
上市日期May 06, 2016
CEODr. John M. Leonard, M.D.
員工數量403
證券類型Ordinary Share
年結日May 06
公司地址40 Erie St Ste 130
城市CAMBRIDGE
上市交易所NASDAQ Global Market Consolidated
國家United States of America
郵編02139-4254
電話18572856200
網址https://www.intelliatx.com/
公司代碼NTLA
上市日期May 06, 2016
CEODr. John M. Leonard, M.D.
Intellia Therapeutics Inc公司高管
名稱
名稱/職務
職務
持股
持股變動
Dr. John M. Leonard, M.D.
Dr. John M. Leonard, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
893.46K
+10.09%
Mr. William J. (Bill) Chase
Mr. William J. (Bill) Chase
Independent Director
Independent Director
119.97K
+500.83%
Ms. Eliana Clark, Ph.D.
Ms. Eliana Clark, Ph.D.
Executive Vice President, Chief Technology Officer
Executive Vice President, Chief Technology Officer
92.38K
-1.09%
Dr. David Lebwohl, M.D.
Dr. David Lebwohl, M.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
51.64K
+125.03%
Dr. Frederick E. (Fred) Cohen, M.D.
Dr. Frederick E. (Fred) Cohen, M.D.
Independent Director
Independent Director
49.72K
+19.18%
Dr. Georgia Keresty, Ph.D.
Dr. Georgia Keresty, Ph.D.
Independent Director
Independent Director
24.15K
+49.55%
Mr. Brian M. Goff
Mr. Brian M. Goff
Independent Director
Independent Director
23.41K
+51.92%
Ms. Muna Bhanji
Ms. Muna Bhanji
Independent Director
Independent Director
18.80K
+74.05%
Dr. Jesse Goodman, M.D.
Dr. Jesse Goodman, M.D.
Independent Director
Independent Director
16.62K
-8.51%
Mr. Michael P. Dube
Mr. Michael P. Dube
Chief Accounting Officer, Vice President
Chief Accounting Officer, Vice President
2.65K
-41.39%
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. John M. Leonard, M.D.
Dr. John M. Leonard, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
893.46K
+10.09%
Mr. William J. (Bill) Chase
Mr. William J. (Bill) Chase
Independent Director
Independent Director
119.97K
+500.83%
Ms. Eliana Clark, Ph.D.
Ms. Eliana Clark, Ph.D.
Executive Vice President, Chief Technology Officer
Executive Vice President, Chief Technology Officer
92.38K
-1.09%
Dr. David Lebwohl, M.D.
Dr. David Lebwohl, M.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
51.64K
+125.03%
Dr. Frederick E. (Fred) Cohen, M.D.
Dr. Frederick E. (Fred) Cohen, M.D.
Independent Director
Independent Director
49.72K
+19.18%
Dr. Georgia Keresty, Ph.D.
Dr. Georgia Keresty, Ph.D.
Independent Director
Independent Director
24.15K
+49.55%
收入明細
FY2025Q2
FY2025Q1
FY2024
FY2023
FY2022
暫無數據
地區USD
名稱
營收
佔比
United States
14.24M
0.00%
業務
地區
暫無數據
股東統計
更新時間: 8月16日 週六
更新時間: 8月16日 週六
持股股東
股東類型
持股股東
持股股東
佔比
ARK Investment Management LLC
10.29%
The Vanguard Group, Inc.
9.52%
BlackRock Institutional Trust Company, N.A.
6.94%
Two Sigma Investments, LP
3.77%
State Street Investment Management (US)
3.49%
其他
65.99%
持股股東
持股股東
佔比
ARK Investment Management LLC
10.29%
The Vanguard Group, Inc.
9.52%
BlackRock Institutional Trust Company, N.A.
6.94%
Two Sigma Investments, LP
3.77%
State Street Investment Management (US)
3.49%
其他
65.99%
股東類型
持股股東
佔比
Investment Advisor
45.92%
Investment Advisor/Hedge Fund
19.79%
Hedge Fund
15.43%
Research Firm
5.09%
Corporation
3.45%
Individual Investor
1.53%
Bank and Trust
0.76%
Pension Fund
0.31%
Sovereign Wealth Fund
0.05%
其他
7.66%
機構持股
更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
685
93.42M
80.66%
-27.55M
2025Q2
701
102.48M
98.83%
-16.17M
2025Q1
734
106.27M
102.60%
-9.72M
2024Q4
721
99.85M
96.57%
-1.86M
2024Q3
722
94.22M
92.84%
-2.81M
2024Q2
726
90.26M
93.51%
-7.71M
2024Q1
739
91.00M
94.49%
-893.96K
2023Q4
792
85.05M
91.49%
-3.09M
2023Q3
802
83.74M
94.78%
-6.96M
2023Q2
821
81.86M
93.61%
-7.70M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
ARK Investment Management LLC
13.02M
12.13%
+6.86K
+0.05%
Jun 30, 2025
The Vanguard Group, Inc.
10.83M
10.09%
+100.14K
+0.93%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
8.04M
7.49%
-367.46K
-4.37%
Jun 30, 2025
Two Sigma Investments, LP
4.37M
4.07%
+394.37K
+9.92%
Jun 30, 2025
State Street Investment Management (US)
4.04M
3.76%
-470.98K
-10.44%
Jun 30, 2025
Regeneron Pharmaceuticals Inc
3.70M
3.45%
--
--
Jun 30, 2025
Baker Bros. Advisors LP
2.68M
2.49%
+2.03M
+315.40%
Jun 30, 2025
Geode Capital Management, L.L.C.
2.61M
2.43%
+126.05K
+5.08%
Jun 30, 2025
Amova Asset Management Co., Ltd.
2.67M
2.49%
-154.10K
-5.45%
Jun 30, 2025
Morgan Stanley Investment Management Inc. (US)
1.96M
1.82%
+783.72K
+66.91%
Jun 30, 2025
查看更多
持股ETF
更新時間: 11月6日 週四
更新時間: 11月6日 週四
機構名稱
佔比
ARK Genomic Revolution ETF
4.33%
WisdomTree BioRevolution Fund
4.13%
Global X Genomics & Biotechnology ETF
1.96%
ARK Innovation ETF
1.82%
Virtus LifeSci Biotech Clinical Trials ETF
1.49%
Invesco Dorsey Wright Healthcare Momentum ETF
1.4%
SPDR S&P Biotech ETF
0.81%
Tema Heart & Health ETF
0.51%
Direxion Daily S&P Biotech Bull 3X Shares
0.43%
Avantis US Small Cap Equity ETF
0.21%
查看更多
ARK Genomic Revolution ETF
佔比4.33%
WisdomTree BioRevolution Fund
佔比4.13%
Global X Genomics & Biotechnology ETF
佔比1.96%
ARK Innovation ETF
佔比1.82%
Virtus LifeSci Biotech Clinical Trials ETF
佔比1.49%
Invesco Dorsey Wright Healthcare Momentum ETF
佔比1.4%
SPDR S&P Biotech ETF
佔比0.81%
Tema Heart & Health ETF
佔比0.51%
Direxion Daily S&P Biotech Bull 3X Shares
佔比0.43%
Avantis US Small Cap Equity ETF
佔比0.21%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
